Panda Preetesh Kumar, Pakeeraiah Kakarla, Mal Suvadeep, Mahapatra Monalisa, Bishoyi Ajit Kumar, Paidesetty Sudhir Kumar
Medicinal Chemistry Research Laboratory, School of Pharmaceutical Sciences, Siksha 'O' Anusandhan (Deemed to be University) Bhubaneswar Odisha 751003 India
Faculty of Pharmacy, C. V. Raman Global University Bhubaneswar Odisha 752054 India.
RSC Med Chem. 2025 Jun 6. doi: 10.1039/d5md00221d.
Superbugs are dominating the world due to the misuse and overuse of antibiotics. This study designed and synthesised two sets of compounds, oxazolones (3a-3j) and their respective imidazolones (4a-4j) bearing a sulfonamide functional group, with increased efficacy and capability to tackle microbial resistance. The structural conformation of compounds was determined using different techniques, including H/C NMR, FT-IR, HRMS and elemental analysis. The binding affinity of the specific targets of these congeners were predicted through molecular docking. The docking results indicated that compounds 4j (-10.36 kcal mol) and 4g (-8.62 kcal mol) showed minimum binding energy with strong affinity against target penicillin-binding protein 2a of methicillin resistant (MRSA) and C14α-demethylase (CYP51) of , respectively. Furthermore, these compounds were investigated for their antimicrobial efficacies. Compared with gentamicin, the imidazolone-derived compounds 4d and 4g showed significant inhibition in-terms of zone of inhibition and MIC values. However, the oxazolone-derived compound 3i showed a maximum zone of inhibition of 20 mm against a MDR strain, which is better than that of ketoconazole. Following these findings, HOMO-LUMO analysis was carried out, and compound 4g showed the smallest energy gap of 3.15 eV. The antibacterial activity of imidazolones is more effective than oxazolones, whereas the action is reversed for fungal strains. To combat against resistant pathogens, multifaced treatments should be followed, and compounds such as 4d and 4g might play a significant role in this regard. The synthetic and biological outcome of the newer vanillyl-imidazolidinyl-sulfamethoxazole derivatives mark a footstep in the drug discovery pipeline in the bacterial resistance era.
由于抗生素的滥用和过度使用,超级细菌正在主宰世界。本研究设计并合成了两组化合物,即带有磺酰胺官能团的恶唑酮(3a - 3j)及其各自的咪唑酮(4a - 4j),它们具有更高的疗效和应对微生物耐药性的能力。使用包括H/C NMR、FT - IR、HRMS和元素分析在内的不同技术确定了化合物的结构构象。通过分子对接预测了这些同系物特定靶点的结合亲和力。对接结果表明,化合物4j(-10.36 kcal/mol)和4g(-8.62 kcal/mol)分别与耐甲氧西林金黄色葡萄球菌(MRSA)的靶标青霉素结合蛋白2a和白色念珠菌的C14α - 脱甲基酶(CYP51)显示出最小结合能和强亲和力。此外,研究了这些化合物的抗菌效果。与庆大霉素相比,咪唑酮衍生的化合物4d和4g在抑菌圈和MIC值方面表现出显著抑制作用。然而,恶唑酮衍生的化合物3i对多重耐药菌株显示出最大抑菌圈为20 mm,优于酮康唑。基于这些发现,进行了HOMO - LUMO分析,化合物4g显示出最小能隙为3.15 eV。咪唑酮的抗菌活性比恶唑酮更有效,而对真菌菌株的作用则相反。为对抗耐药病原体,应采用多方面治疗方法,化合物4d和4g等可能在这方面发挥重要作用。新型香草基 - 咪唑烷基 - 磺胺甲恶唑衍生物的合成和生物学结果标志着在细菌耐药时代药物发现管道中的一个进展。